Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain
R Aldrin Denny1, Andrew C Flick2, Jotham Coe2
1Medicine Design, Pfizer , 610 Main Street, Cambridge Massachusetts 02139, United States.
Abstract:
Chemical probes are required for preclinical target validation to interrogate novel biological targets and pathways. Selective inhibitors of the CREB binding protein (CREBBP)/EP300 bromodomains are required to facilitate the elucidation of biology associated with these important epigenetic targets. Medicinal chemistry optimization that paid particular attention to physiochemical properties delivered chemical probes with desirable potency, selectivity, and permeability attributes. An important feature of the optimization process was the successful application of rational structure-based drug design to address bromodomain selectivity issues (particularly against the structurally related BRD4 protein).
Related Concept Videos
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Cooperative Binding of Transcription Regulators
Drug-Receptor Bonds
In...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...


